Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF and EPO in ACLF
NCT01383460Phase 3Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jul 2011
- Primary completion
- Jan 2013
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
A Phase 3 trial of filgrastim, darbepoetin alfa in acute-on-chronic liver failure (ACLF), sponsored by Institute of Liver and Biliary Sciences. Started Jul 2011; status: completed.
02
Drugs
filgrastimdarbepoetin alfa
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT01383460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01383460.